Endometrial Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight's, "Endometrial Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Endometrial Cancer pipeline landscape. It covers the Endometrial Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Endometrial Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Endometrial Cancer Research. Learn more about our innovative pipeline today! @ Endometrial Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Endometrial Cancer Pipeline Report

* June 2024:- Merch Sharp & Dohme LLC - A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001). The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.
* June 2024:- Faeth Therapeutics - A Randomized, Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced or Recurrent Endometrial Cancer. This is a Phase 2, multicenter, open-label, randomized study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel and the efficacy and safety of serabelisib with paclitaxel versus paclitaxel alone in participants with advanced or recurrent endometrial cancer.
* June 2024:- Karyopharm Therapeutics Inc. - A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.
* DelveInsight's Endometrial Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Endometrial Cancer treatment.
* The leading Endometrial Cancer Companies such as Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix , and others.
* Promising Endometria Cancer Therapies such as Sacituzumab Govitecan, Ataluren + Pembrolizumab, Olaparib, Lenvatinib, Paclitaxel, BMS- 986205, Sapanisertib, Serabelisib, and others.

Stay informed about the cutting-edge advancements in Endometrial Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Endometrial Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Endometrial Cancer Emerging Drugs Profile

LENVIMA: Merck & Co

Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFR), KIT, and RET. LENVIMA is being developed in combination with KEYTRUDA. LENVIMA is being developed in collaboration with Eisai. Currently, the drug is in Phase III stage of its development for the treatment of endometrial cancer.

Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FR)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. Currently, the drug is in Phase II stage of its development for the treatment of endometrial cancer.

XMT 1660: Mersana Therapeutics

XMT-1660 is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary payload with controlled bystander effect. B7-H4 is overexpressed in a range of cancers, including breast, endometrial and ovarian tumors. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. Currently, the drug is in Phase I stage of its development for the treatment of endometrial cancer.

VLS-1488: Volastra Therapeutics, Inc.

VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. VLS-1488 and sovilnesib (formally AMG650) make up Volastra's innovative clinical portfolio of differentiated KIF18A inhibitors specifically designed for the treatment of solid tumors characterized by high levels of chromosomal instability (CIN). Currently, the drug is in Phase I/II stage of its development for the treatment of endometrial cancer.

Learn more about Endometrial Cancer Drugs opportunities in our groundbreaking Endometrial Cancer Research and development projects @ Endometrial Cancer Unmet Needs [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Endometrial Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Subcutaneous
* Intravenous
* Oral
* Intramuscular

Endometrial Cancer Products have been categorized under various Molecule types such as

* Small molecules
* Natural metabolites
* Monoclonal antibodies

Discover the latest advancements in Endometrial Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Endometrial Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Endometrial Cancer Pipeline Report

* Coverage- Global
* Endometrial Cancer Companies- Merck & Co, ImmunoGen, Mersana Therapeutics, Volastra Therapeutics, Inc, BeiGene/Jazz Pharmaceuticals, Iconic Therapeutics, AstraZeneca/Daiichi Sankyo, Apollomics, Tempest Therapeutics, Totus Medicines, TORL Biotherapeutics, Tango Therapeutics, Theratechnologies, Synthon, Klus Pharma, Seagen, Karyopharm Therapeutics, Inspirna, Chimerix, and others.
* Endometria Cancer Therapies- Sacituzumab Govitecan, Ataluren + Pembrolizumab, Olaparib, Lenvatinib, Paclitaxel, BMS- 986205, Sapanisertib, Serabelisib, and others.
* Endometrial Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Endometrial Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Endometrial Cancer Pipeline on our website @ Endometrial Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/endometrial-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Endometrial Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Endometrial Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* LENVIMA: Merck & Co
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Mirvetuximab soravtansine: ImmunoGen
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* VLS-1488: Volastra Therapeutics, Inc.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Endometrial Cancer Key Companies
* Endometrial Cancer Key Products
* Endometrial Cancer - Unmet Needs
* Endometrial Cancer - Market Drivers and Barriers
* Endometrial Cancer - Future Perspectives and Conclusion
* Endometrial Cancer Analyst Views
* Endometrial Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometrial-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.